-
Founded in:
1998-02-11 -
Country:
China -
Address:
No. 46, Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province -
Tax NO.:
91330000704676287N -
Registered Funds:
1,207,873,716 yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Aztreonam |
Extract from the above information
More
Extract from the above information |
78110-38-0 | 31 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| TOLBUTAMIDE |
This product is a hypoglycemic drug. 1. It stimulates the pancreatic islet beta cells to secrete insulin, which presupposes that the islet beta cells also have a certain ability to synthesize and secrete insulin; 2. It inhibits liver glycogenolysis and gluconeogenesis by increasing portal vein insulin levels or directly acting on the liver, and reduces the generation and output of glucose in the liver; 3. It may also increase the sensitivity of extrapancreatic tissues to insulin and the utilization of sugar (probably mainly through post-receptor effects). Therefore, the overall effect is to reduce fasting blood sugar and postprandial blood sugar.
More
This product is a hypoglycemic drug. 1. It stimulates the pancreatic islet beta cells to secrete insulin, which presupposes that the islet beta cells also have a certain ability to synthesize and secrete insulin; 2. It inhibits liver glycogenolysis and gluconeogenesis by increasing portal vein insulin levels or directly acting on the liver, and reduces the generation and output of glucose in the liver; 3. It may also increase the sensitivity of extrapancreatic tissues to insulin and the utilization of sugar (probably mainly through post-receptor effects). Therefore, the overall effect is to reduce fasting blood sugar and postprandial blood sugar. |
64-77-7 | 16 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Zolmitriptan |
Zolmitriptan shows high affinity to human recombinant 5-HT1D and 5-HT1B receptors, and moderate affinity to 5-HT1A receptors. The N-desmethyl metabolite of this product also shows high affinity to 5-HT1B/1D receptors, and moderate affinity to 5-HT1A receptors. It is currently believed that the onset of migraine is related to local cranial vasodilation and/or the release of sensory neuropeptides (vasoactive intestinal peptide, substance P, calcitonin gene-related peptide) from nerve endings of the trigeminal nervous system. The therapeutic effect of this product on migraine may be through the stimulating effect on the 5-HT1B/1D receptors of intracranial blood vessels (including arteriovenous anastomoses) and sensory nerves of the trigeminal nervous system, resulting in cranial vasoconstriction and inhibition of the release of post-inflammatory neuropeptides.
More
Zolmitriptan shows high affinity to human recombinant 5-HT1D and 5-HT1B receptors, and moderate affinity to 5-HT1A receptors. The N-desmethyl metabolite of this product also shows high affinity to 5-HT1B/1D receptors, and moderate affinity to 5-HT1A receptors. It is currently believed that the onset of migraine is related to local cranial vasodilation and/or the release of sensory neuropeptides (vasoactive intestinal peptide, substance P, calcitonin gene-related peptide) from nerve endings of the trigeminal nervous system. The therapeutic effect of this product on migraine may be through the stimulating effect on the 5-HT1B/1D receptors of intracranial blood vessels (including arteriovenous anastomoses) and sensory nerves of the trigeminal nervous system, resulting in cranial vasoconstriction and inhibition of the release of post-inflammatory neuropeptides. |
139264-17-8 | 38 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Norfloxacin |
This product is a fluoroquinolone antibacterial drug with a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria. It acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death. It has effects on both Gram-positive and Gram-negative bacteria. Bacteria are not easy to develop resistance to this product, and there is no cross-resistance between similar drugs and antibiotics.
More
This product is a fluoroquinolone antibacterial drug with a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria. It acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death. It has effects on both Gram-positive and Gram-negative bacteria. Bacteria are not easy to develop resistance to this product, and there is no cross-resistance between similar drugs and antibiotics. |
70458-96-7 | 35 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Lansoprazole |
Extract from the above information
More
Extract from the above information |
103577-45-3 | 88 |